The Priority Review

Tag

Stream

353 stories · page 5 of 30

Stories

  1. Approvals

    Abbisko's PIMJETMI receives U.S. FDA approval for TGCT

    The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.

  2. Clinical trials

    NEB and Mammoth Biosciences launch MB-CasFire enzyme for one-pot isothermal assays

    NEB will manufacture and globally distribute Mammoth Biosciences' proprietary MB-CasFire enzyme, a thermostable Type V CRISPR nuclease that works across 37-65 °C and can be coupled directly with LAMP, RPA and NEAR assays. MB-CasFire resolves targets at single-nucleotide resolution and simplifies assay architecture by eliminating the need for multiple temperature incubations or component additions.

  3. Approvals

    FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor

    On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.

  4. Policy

    Eli Lilly launches Life Doesn't Slow Down campaign for Foundayo

    The company announced a new campaign encouraging patients to discuss weight-loss options with doctors. The campaign highlights Foundayo, a GLP-1 pill approved by the FDA in April 2026, and features comedian Leanne Morgan as a spokesperson.

  5. Policy

    IMVIONIX acquires U.S. and Canadian rights to BEOVU

    IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema.

  6. Clinical trials

    ISTx registers Phase 3 trial of ceftobiprole in pediatric Staphylococcus aureus bacteremia

    The study, led by ISTx, LLC, plans to enroll 60 participants and begin on October 30, 2026, to compare ceftobiprole with standard-of-care antibiotics in children under 18 with Staphylococcus aureus bacteremia, including right-sided infective endocarditis. The trial will also evaluate safety, tolerability, efficacy, and pharmacokinetics of ceftobiprole.

  7. Clinical trials

    Sanofi registers Phase 3 trial of venglustat vs Cerezyme in pediatric Gaucher disease type 3

    The study, titled LEAP2KIDS, plans to enroll 18 pediatric participants aged 2 to 11 years with Gaucher Disease Type III who have reached therapeutic goals with enzyme replacement therapy. It is a randomized, open-label, active-comparator trial with a 52-week primary analysis period and a 52-week extended treatment period.

  8. Clinical trials

    Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer

    The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.

  9. Clinical trials

    Apellis posts results of Pegcetacoplan long-term safety extension study

    The study, completed on September 4, 2025, enrolled 137 participants who had previously completed a pegcetacoplan study. It was an open-label, non-randomized, multi-center Phase 3 extension study evaluating long-term safety and efficacy in PNH.

  10. Clinical trials

    Alcon posts results of Phase 3 FID 123320 study

    The study enrolled 284 participants and was completed with results first posted on ClinicalTrials.gov on November 10, 2026. It assessed the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) versus vehicle for relieving ocular redness in pediatric and adult populations.

  11. Clinical trials

    Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China

    Results for the study were first posted on ClinicalTrials.gov on November 10, 2026. The trial enrolled 72 participants who were randomized to receive epcoritamab or investigator's choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.

  12. Clinical trials

    Alcon posts results of Phase 3 apraclonidine study for ocular redness

    The study enrolled 159 participants and was completed on November 14, 2024. Results were first posted on ClinicalTrials.gov on November 10, 2026.